Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia

LJ. Verboon, A. Obulkasim, JD. de Rooij, JE. Katsman-Kuipers, E. Sonneveld, A. Baruchel, J. Trka, D. Reinhardt, R. Pieters, J. Cloos, GJ. Kaspers, JH. Klusmann, CM. Zwaan, M. Fornerod, MM. van den Heuvel-Eibrink,

. 2016 ; 7 (30) : 48412-48422.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011139

The most important reason for therapy failure in pediatric acute myeloid leukemia (AML) is relapse. In order to identify miRNAs that contribute to the clonal evolution towards relapse in pediatric AML, miRNA expression profiling of 127 de novo pediatric AML cases were used. In the diagnostic phase, no miRNA signatures could be identified that were predictive for relapse occurrence, in a large pediatric cohort, nor in a nested mixed lineage leukemia (MLL)-rearranged pediatric cohort. AML with MLL- rearrangements are found in 15-20% of all pediatric AML samples, and reveal a relapse rate up to 50% for certain translocation partner subgroups. Therefore, microRNA expression profiling of six paired initial diagnosis-relapse MLL-rearranged pediatric AML samples (test cohort) and additional eight paired initial diagnosis-relapse samples with MLL-rearrangements (validation cohort) was performed. A list of 53 differentially expressed miRNAs was identified of which the miR-106b~25 cluster, located in intron 13 of MCM7, was the most prominent. These differentially expressed miRNAs however could not predict a relapse in de novo AML samples with MLL-rearrangements at diagnosis. Furthermore, higher mRNA expression of both MCM7 and its upstream regulator E2F1 was found in relapse samples with MLL-rearrangements. In conclusion, we identified the miR-106b~25 cluster to be upregulated in relapse pediatric AML with MLL-rearrangements.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011139
003      
CZ-PrNML
005      
20180404142558.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.10270 $2 doi
035    __
$a (PubMed)27351222
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Verboon, Lonneke J $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
245    10
$a MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia / $c LJ. Verboon, A. Obulkasim, JD. de Rooij, JE. Katsman-Kuipers, E. Sonneveld, A. Baruchel, J. Trka, D. Reinhardt, R. Pieters, J. Cloos, GJ. Kaspers, JH. Klusmann, CM. Zwaan, M. Fornerod, MM. van den Heuvel-Eibrink,
520    9_
$a The most important reason for therapy failure in pediatric acute myeloid leukemia (AML) is relapse. In order to identify miRNAs that contribute to the clonal evolution towards relapse in pediatric AML, miRNA expression profiling of 127 de novo pediatric AML cases were used. In the diagnostic phase, no miRNA signatures could be identified that were predictive for relapse occurrence, in a large pediatric cohort, nor in a nested mixed lineage leukemia (MLL)-rearranged pediatric cohort. AML with MLL- rearrangements are found in 15-20% of all pediatric AML samples, and reveal a relapse rate up to 50% for certain translocation partner subgroups. Therefore, microRNA expression profiling of six paired initial diagnosis-relapse MLL-rearranged pediatric AML samples (test cohort) and additional eight paired initial diagnosis-relapse samples with MLL-rearrangements (validation cohort) was performed. A list of 53 differentially expressed miRNAs was identified of which the miR-106b~25 cluster, located in intron 13 of MCM7, was the most prominent. These differentially expressed miRNAs however could not predict a relapse in de novo AML samples with MLL-rearrangements at diagnosis. Furthermore, higher mRNA expression of both MCM7 and its upstream regulator E2F1 was found in relapse samples with MLL-rearrangements. In conclusion, we identified the miR-106b~25 cluster to be upregulated in relapse pediatric AML with MLL-rearrangements.
650    _2
$a mladiství $7 D000293
650    _2
$a karcinogeneze $x genetika $7 D063646
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a klonální evoluce $7 D060965
650    _2
$a kohortové studie $7 D015331
650    _2
$a transkripční faktor E2F1 $x metabolismus $7 D050687
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a histonlysin-N-methyltransferasa $x genetika $x metabolismus $7 D011495
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a introny $x genetika $7 D007438
650    _2
$a akutní myeloidní leukemie $x genetika $x patologie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a MCM komplex, komponenta 7 $x metabolismus $7 D064168
650    _2
$a multigenová rodina $7 D005810
650    _2
$a protoonkogenní protein MLL $x genetika $7 D051788
650    _2
$a lokální recidiva nádoru $x genetika $x patologie $7 D009364
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a translokace genetická $7 D014178
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
700    1_
$a Obulkasim, Askar $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
700    1_
$a de Rooij, Jasmijn D E $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
700    1_
$a Katsman-Kuipers, Jenny E $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
700    1_
$a Sonneveld, Edwin $u Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands.
700    1_
$a Baruchel, André $u Department of Hematology, Hopital Saint- Louis, Paris, France.
700    1_
$a Trka, Jan $u Department of Pediatric Hematology/Oncology, 2nd Medical School, Charles University, Prague, Czech Republic.
700    1_
$a Reinhardt, Dirk $u Clinic for Pediatrics III, University Hospital Essen, Essen, Germany.
700    1_
$a Pieters, Rob $u Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
700    1_
$a Cloos, Jacqueline $u Paediatric Oncology/Haematology, VU University Medical Centre, Amsterdam, The Netherlands.
700    1_
$a Kaspers, Gertjan J L $u Paediatric Oncology/Haematology, VU University Medical Centre, Amsterdam, The Netherlands.
700    1_
$a Klusmann, Jan-Henning $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a Zwaan, Christian Michel $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
700    1_
$a Fornerod, Maarten $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
700    1_
$a van den Heuvel-Eibrink, Marry M $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands. Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 30 (2016), s. 48412-48422
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27351222 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142638 $b ABA008
999    __
$a ok $b bmc $g 1288624 $s 1007951
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 30 $d 48412-48422 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180404
Back

Find record

Citation metrics

Archiving options